ReviewJournal of neurology2017
Posterior reversible encephalopathy syndrome.
Review in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 250 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
250 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Clinical, Laboratory and Radiological Factors associated with posterior reversible encephalopathy syndrome (PRES) in patients with eclampsia or pre-eclampsia: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Consecutive PRES and diffuse alveolar hemorrhage in a patient with active lupus nephritis and antiphospholipid antibodies: a case report and systematic literature review.BMC nephrology · 2026Pooled it
- Clinical characteristics and risk factors for bilateral lateral geniculate body pathology: a systematic review of the literature.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Pooled it
- Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome in patients with COVID-19 infection: is there a link? A systematic review and case report analysis.Journal of neurology · 2023Pooled it
- Brain MRI findings in COVID-19 patients with PRES: A systematic review.Clinical imaging · 2022Pooled it
- Posterior reversible encephalopathy syndrome following eclampsia in a primigravida at 35 weeks of gestation: A case report.Radiology case reports · 2026Article
- Tacrolimus-Induced Atypical Posterior Reversible Encephalopathy Syndrome (PRES) in a Kidney Transplant Recipient: A Case Report.Clinical case reports · 2026Article
- Article
- Article
- Article
- Article
- Clinical utility of Arterial Spin Labeling perfusion images in pediatric neurological emergencies.La Radiologia medica · 2026Review
- Posterior Reversible Encephalopathy Syndrome (PRES) and intraventricular hemorrhage in a patient with untreated hypertension: a case report.International journal of emergency medicine · 2026Article
- Posterior reversible encephalopathy syndrome in drug-induced syndrome of inappropriate ADH secretion: a case report.Journal of medical case reports · 2026Article
- Systemic Immune-Inflammation Index and Clinical Predictors of Atypical PRES in Eclampsia: Higher Blood Pressure and Inflammatory Burden Drive Multi-Regional Involvement.Biomedicines · 2026Article
- Article
- Posterior Reversible Encephalopathy Syndrome in Peritoneal Dialysis Patients: A Four-Case Series.Journal of clinical medicine · 2026Article
- Acute Neurological Complications After Transplantation in Methylmalonic Acidemia: A 35-Patient French Cohort.Journal of inherited metabolic disease · 2026Article
- Article
- Posterior reversible encephalopathy syndrome due to pituitrin for bronchiectasis with hemoptysis--a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
190 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The posterior reversible encephalopathy syndrome (PRES) is a neurological disorder of (sub)acute onset characterized by varied neurological symptoms, which may include headache, impaired visual acuity or visual field deficits, disorders of consciousness, confusion, seizures, and focal neurological deficits. In a majority of patients the clinical presentation includes elevated arterial blood pressure up to hypertensive emergencies. Neuroimaging, in particular magnetic resonance imaging, frequently shows a distinctive parieto-occipital pattern with a symmetric distribution of changes reflecting vasogenic edema. PRES frequently develops in the context of cytotoxic medication, (pre)eclampsia, sepsis, renal disease or autoimmune disorders. The treatment is symptomatic and is determined by the underlying condition. The overall prognosis is favorable, since clinical symptoms as well as imaging lesions are reversible in most patients. However, neurological sequelae including long-term epilepsy may persist in individual cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.